Literature DB >> 1658387

Immunological elimination of infected cells as the candidate mechanism for tumor protection in polyomavirus-infected mice.

J J Wirth1, M M Fluck.   

Abstract

The uniformly lethal development of mammary tumors in polyomavirus-infected adult female nude mice was prevented by adoptive cell transfer of polyomavirus-immune splenocytes or peritoneal cells. Transferred immune cells also lowered the growth rate of emerging tumors. The induction of other relatively less frequent tumors of the skin and bone was decreased as well. Using in situ hybridization of whole-body sections as well as hybridization of nucleic acids from the mammary glands, we show for the first time that transferred immune cells, but not normal cells, virtually eliminated virus signal in the whole mouse and in the mammary glands. Since infected and tumorous mammary glands produce very little infectious virus, it appears that a major mechanism mediating the prevention of polyomavirus oncogenesis involves the immunological elimination of nonproductively and persistently infected cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658387      PMCID: PMC250812     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Influence of total body x-irradiation on tumor induction by parotid tumor agent in adult mice.

Authors:  L W LAW; C J DAWE
Journal:  Proc Soc Exp Biol Med       Date:  1960-11

2.  Prevention of virus-induced neoplasms in mice through passive transfer of immunity by sensitized syngeneic lymphoid cells.

Authors:  L W Law; R C Ting; E Leckband
Journal:  Proc Natl Acad Sci U S A       Date:  1967-04       Impact factor: 11.205

3.  Tumour prevention and rejection with recombinant vaccinia.

Authors:  R Lathe; M P Kieny; P Gerlinger; P Clertant; I Guizani; F Cuzin; P Chambon
Journal:  Nature       Date:  1987 Apr 30-May 6       Impact factor: 49.962

4.  Polyomavirus tumor induction in mice: influences of viral coding and noncoding sequences on tumor profiles.

Authors:  R Freund; G Mandel; G G Carmichael; J P Barncastle; C J Dawe; T L Benjamin
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

5.  Pattern of polyomavirus replication from infection until tumor formation in the organs of athymic nu/nu mice.

Authors:  J Demengeot; J Jacquemier; M Torrente; D Blangy; M Berebbi
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Specific thymus-derived (T) cell recognition of papova virus-transformed cells.

Authors:  M I Greene; L L Perry; E Kinney-Thomas; T L Benjamin
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

7.  A polyomavirus tumor-specific transplantation antigen (TSTA) epitope is situated within the N-terminal amino acid sequence common to middle and small T-antigens.

Authors:  G Reinholdsson; T Ramqvist; J Brandberg; T Dalianis
Journal:  Virology       Date:  1988-10       Impact factor: 3.616

8.  Specific tissue targeting of polyoma virus oncogenicity in athymic nude mice.

Authors:  M Berebbi; L Dandolo; J Hassoun; A M Bernard; D Blangy
Journal:  Oncogene       Date:  1988-02       Impact factor: 9.867

9.  Clearance of a persistent paramyxovirus infection is mediated by cellular immune responses but not by serum-neutralizing antibody.

Authors:  D F Young; R E Randall; J A Hoyle; B E Souberbielle
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

10.  Variations in polyoma virus genotype in relation to tumor induction in mice. Characterization of wild type strains with widely differing tumor profiles.

Authors:  C J Dawe; R Freund; G Mandel; K Ballmer-Hofer; D A Talmage; T L Benjamin
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

View more
  8 in total

1.  Expression of major capsid protein VP-1 in the absence of viral particles in thymomas induced by murine polyomavirus.

Authors:  N Sanjuan; A Porrás; J Otero; S Perazzo
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Detection of human polyomavirus 7 in human thymic epithelial tumors.

Authors:  Dorit Rennspiess; Sreedhar Pujari; Marlies Keijzers; Myrurgia A Abdul-Hamid; Monique Hochstenbag; Anne-Marie Dingemans; Anna Kordelia Kurz; Ernst-Jan Speel; Anke Haugg; Diana V Pastrana; Christopher B Buck; Marc H De Baets; Axel Zur Hausen
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

3.  Systemic polyomavirus genome increase and dissemination of capsid-defective genomes in mammary gland tumor-bearing mice.

Authors:  J J Wirth; L Chen; M M Fluck
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Acute, lethal, natural killer cell-resistant myeloproliferative disease induced by polyomavirus in severe combined immunodeficient mice.

Authors:  E Szomolanyi-Tsuda; P L Dundon; I Joris; L D Shultz; B A Woda; R M Welsh
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

Review 5.  Mammary tumors induced by polyomavirus.

Authors:  M M Fluck; S Z Haslam
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Antiviral CD8+ T cell responses in neonatal mice: susceptibility to polyoma virus-induced tumors is associated with lack of cytotoxic function by viral antigen-specific T cells.

Authors:  J M Moser; J D Altman; A E Lukacher
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

7.  Low prevalence of Merkel cell polyomavirus in human epithelial thymic tumors.

Authors:  Emil Chteinberg; Faisal Klufah; Dorit Rennspiess; Mick F Mannheims; Myrurgia A Abdul-Hamid; Mario Losen; Marlies Keijzers; Marc H De Baets; Anna Kordelia Kurz; Axel Zur Hausen
Journal:  Thorac Cancer       Date:  2019-01-09       Impact factor: 3.500

8.  Expression of pRb and p16INK4 in human thymic epithelial tumors in relation to the presence of human polyomavirus 7.

Authors:  Marlies Keijzers; Dorit Rensspiess; Sreedhar Pujari; Myrurgia A Abdul-Hamid; Monique Hochstenbag; Anne-Marie Dingemans; Anna Kordelia Kurz; Anke Haugg; Jos G Maessen; Marc H De Baets; Axel Zur Hausen
Journal:  Diagn Pathol       Date:  2015-11-04       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.